In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS?

Biomed Pharmacother. 1994;48(2):51-3. doi: 10.1016/0753-3322(94)90075-2.

Abstract

Simultaneous administration of zidovudine, acriflavine and celliptium to Friend virus-injected mice eradicates the virus, as evidenced by the impossibility of the treated-mouse serum, when injected to virgin recipients, to induce spleen foci formation. An adapted preliminary protocol given to patients in whose p 24 antigen was present in the blood, lead to a considerable reduction of that marker. The cures lasted 3 weeks, and were repeated after 3-week intervals. Since p 24 antigen returns to pre-treatment levels at the end of the interval, research should concentrate on the maintenance of the effect during the interval.

MeSH terms

  • AIDS-Related Complex / drug therapy*
  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acriflavine / administration & dosage*
  • Acriflavine / pharmacology
  • Acriflavine / therapeutic use
  • Animals
  • Drug Therapy, Combination
  • Ellipticines / administration & dosage*
  • Ellipticines / pharmacology
  • Ellipticines / therapeutic use
  • Friend murine leukemia virus / drug effects*
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Mice
  • Mice, Inbred DBA
  • Zidovudine / administration & dosage*
  • Zidovudine / pharmacology
  • Zidovudine / therapeutic use

Substances

  • Ellipticines
  • Acriflavine
  • Zidovudine